产品
  • 产品
  • 供应商
  • 采购
  • 资讯
  • 会展
猜你想搜
首页 制药产品大全 原料药 抗感染药物原料 (3S)-N-[5-[(2R)...

(3S)-N-[5-[(2R)-2-(2,5-二氟苯基)-1-吡咯烷基]吡唑并[1,5-a]嘧啶-3-基]-3-羟基-1-吡咯烷甲酰胺硫酸盐

2026-05-09
 
1223405-08-0
中国药典
医药级别

产品详情

(3S)-N-[5-[(2R)-2-(2,5-二氟苯基)-1-吡咯烷基]吡唑并[1,5-a]嘧啶-3-基]-3-羟基-1-吡咯烷甲酰胺硫酸盐
其他抗感染类
1223405-08-0
中国药典
医药级别
纯度99%
1千克
100
款到发货
3天
北美洲,中/南美洲,西欧,东欧,大洋洲,亚洲,中东,非洲
是
仅供研发

产品描述

商品名称 
CAS号 1223405-08-0
分子式 C21H24F2N6O6S
分子量 526.51400
LogP 3.45140
PSA 168.98000
产品描述:loxo-101 is a small molecule that was designed to block the atp binding site of the trk family of receptors, with 2 to 20 nm cellular potency against the trka, trkb, and trkc kinases. ic50 value: 2 - 20 nm target: trka/b/c in vitro: loxo-101 is an orally administered inhibitor of the trk kinase and is highly selective only for the trk family of receptors. loxo-101 is evaluated for off-target kinase enzyme inhibition against a panel of 226 non-trk kinases at a compound concentration of 1,000 nm and atp concentrations near the km for each enzyme. in the panel, loxo-101 demonstrates greater than 50% inhibition for only one non-trk kinase (tnk2 ic50, 576 nm). measurement of proliferation following treatment with loxo-101 demonstrates a dose-dependent inhibition of cell proliferation in all three cell lines. the ic50 is less than 100 nm for cuto-3.29 and less than 10 nm for km12 and mo-91, consistent with the known potency of this drug for the trk kinase family. [1] loxo-101 demonstrates potent and highly-selective inhibition of trka, trkb, and trkc over other kinase- and non-kinase targets. loxo-101 is a potent, atp-competitive trk inhibitor with ic50s in low nanomolar range for inhibition of all trk family members in binding and cellular assays, with 100x selectivity over other kinases. [2] in vivo: athymic nude mice injected with km12 cells are treated with loxo-101 orally daily for 2 weeks. dose-dependent tumor inhibition is observed, demonstrating the ability of this selective compound to inhibit tumor growth in vivo. 
 

安徽海康药业股份有限公司
访问店铺
注册资本
公司地址
联系人
邮箱

公司简介

安徽海康药业股份有限公司成立于2009年,是一家生产抗病毒、抗肿瘤、降糖、抗过敏等高端原料药的高新技术企业。公司前身在浙江拥有20多年抗病毒、糖尿病和抗肿瘤等原料药生产经验。顺应时代变迁,整个企业搬迁到安徽安庆,注册资金2250 万元,注册地址为安徽省安庆市大观区环城西路 21 号。历经多年的发展,目前研发团队、质量部人员和EHS管理人员35人,总人数90余人,本科以上技术人员25名。公司与华东师范大学、安徽大学、浙江工业大学、中国药科大学以及安庆大学达成合作,作为本科毕业生和研究生实习基地。 公司现已建成投产一期工程,获得排污许可证,完成职业卫生防治验收,顺利取得“三级安全生产标准化”证书和药品生产许可证。 公司2022年投资建设二期工程,建设两栋总面积为10000平方的GMP原料药生产车间;8000平方的研发楼和仓库,二期投产产值预计达到肆亿元人民币!
业务类型:
成立日期:
年营业额:
主营产品类别: